Fujifilm Diosynth Biotechnologies has announced a major expansion aimed at rapidly growing its biologics manufacturing prowess.
This week, the parent company, Fujifilm Corporation, announced that it is pumping $850 million into growing its bio CDMO subsidiary, Fujifilm Diosynth.
The investment will have the biggest impact on the company’s UK operations, where Fujifilm expects to increase its gene therapy production ten-fold, while also tripling cell culture capacity and doubling microbial fermentation output at its 5,000L scale facility.
But the U.S. will also be infused with fresh capital, where the company plans to double cell culture production for recombinant vaccines.
The company says that increased demand for its outsourcing processing, analytical services, bulk drug substance manufacturing, and fill/finish operations are being driven by growth in COVID-19-related products, and antibody and gene therapies.
FujiFilm says the expansions to become operational in late 2023.